Curanex Pharmaceuticals executes 1-for-20 reverse stock split - CURX News | RalliesCuranex Pharmaceuticals executes 1-for-20 reverse stock split
C
CURX• Reverse split and Nasdaq compliance
- Curanex Pharmaceuticals executed a 1-for-20 reverse stock split on Aug. 20, 2026 to regain Nasdaq minimum bid price compliance.
- Nasdaq confirmed the stock traded at $1 or higher for 10 straight sessions from Aug. 20 to Sept. 2, 2026.
- The company regained compliance with Nasdaq Listing Rule 5550(a)(2), closing the listing matter on Sept. 3, 2026.
•
